1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-ethyl-2-imino-2,3-dihydro-1H-benzimidazol-1-yl)ethanone hydrochloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-ethyl-2-imino-2,3-dihydro-1H-benzimidazol-1-yl)ethanone hydrochloride
• 英文别名: 1-(3,5-ditert-butyl-4-hydroxyphenyl)-2-(3-ethyl-2-iminobenzimidazol-1-yl)ethanone;hydrochloride
• 化学式: C25H34ClN3O2
• 分子量: 444.0
• InChiKey: RXJVBZXGRRERAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.55
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  67.6
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
  申请人：The Regents of the University of California

  公开号：US11419883B2

  公开（公告）日：2022-08-23

  The inventor of the present disclosure has advantageously elucidated the role of senescent processes in the development of Type 1 diabetes. Genotoxic stress responses, senescence, and acquisition of a SASP condition in beta cells are drivers that progress at-risk individuals to overt Type 1 diabetes. The administration of senolytic agents to at risk individuals selectively removes senescent cells and relieves beta cells from the factors which drive the development of overt Type 1 diabetes. Accordingly, Type 1 diabetes can be prevented in at-risk individuals by the administration of senolytic compositions. Additionally, given the major role of SASP in the development of Type 1 diabetes, the inhibition of SASP factors may be used to prevent Type 1 diabetes.

  本公开内容的发明者以其优势阐明了衰老过程在 1 型糖尿病发展中的作用。基因毒性应激反应、衰老和β细胞获得 SASP 状态是高危人群发展为明显 1 型糖尿病的驱动因素。对高危人群施用衰老分解剂，可选择性地清除衰老细胞，并使β细胞免受驱动明显的1型糖尿病发展的因素的影响。因此，对高危人群施用衰老分解组合物可以预防 1 型糖尿病。此外，鉴于 SASP 在 1 型糖尿病发病过程中的重要作用，抑制 SASP 因子可用于预防 1 型糖尿病。
• Inhibiting Senescent Processes in Beta Cells for the Prevention of Type 1 Diabetes
  申请人：The Regents of the University of California

  公开号：US20200078376A1

  公开（公告）日：2020-03-12

  The inventor of the present disclosure has advantageously elucidated the role of senescent processes in the development of Type 1 diabetes. Genotoxic stress responses, senescence, and acquisition of a SASP condition in beta cells are drivers that progress at-risk individuals to overt Type 1 diabetes. The administration of senolytic agents to at risk individuals selectively removes senescent cells and relieves beta cells from the factors which drive the development of overt Type 1 diabetes. Accordingly, Type 1 diabetes can be prevented in at-risk individuals by the administration of senolytic compositions. Additionally, given the major role of SASP in the development of Type 1 diabetes, the inhibition of SASP factors may be used to prevent Type 1 diabetes.